No antithrombotic therapy versus single antiplatelet therapy after percutaneous left atrial appendage closure in non-valvular atrial fibrillation: rationale and design of the multicentre, randomised, non-inferiority NAPT-LAAC trial

-VA score ≥2 and who successfully undergo LAAC are eligible for inclusion. A total of 500 patients undergoing LAAC will be randomised (1:1) to aspirin monotherapy versus non-antithrombotic therapy for the 45 days following OAC monotherapy. The primary outcome is a composite of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, and clinically relevant non-fatal bleeding during a maximum of 4 years of follow-up. Major bleeding or clinically relevant non-fatal bleeding is defined as Type 2, 3, or 5 bleeding, according to the Bleeding Academic Research Consortium definition. The NAPT-LAAC trial will determine the probable non-inferiority of long-term non-antithrombotic therapy to aspirin monotherapy in patients with NVAF who undergo LAAC. (ClinicalTrials.gov: NCT07125417; jRCTs031250110).

Authors

Institutions

Publication Details

Journal
EuroIntervention
Published
2026-04-01
DOI
https://doi.org/10.4244/eij-d-25-01307
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

No antithrombotic therapy versus single antiplatelet therapy after percutaneous left atrial appendage closure in non-valvular atrial fibrillation: rationale and design of the multicentre, randomised, non-inferiority NAPT-LAAC trial

Takao Morikawa, Atsushi Sugiura, Tomoyuki Tani, Daisuke Hachinohe et al.
EuroIntervention
Atrial Fibrillation Management and Outcomes
article

No antithrombotic therapy versus single antiplatelet therapy after percutaneous left atrial appendage closure in non-valvular atrial fibrillation: rationale and design of the multicentre, randomised, non-inferiority NAPT-LAAC trial

Takao Morikawa, Atsushi Sugiura, Tomoyuki Tani, Daisuke Hachinohe, Mike Saji, Toshiaki Otsuka, Masaki Nakashima, Masahiko Asami, Kentaro Hayashida, Yohei Ohno, Masaki Izumo, Toru Naganuma, Shunsuke Kubo, Tetsuro Shimura, Yuki Izumi, on behalf of the OCEAN-LAAC investigators, Yusuke Watanabe, Gaku Nakazawa, Shinichi Shirai, Shinya Okazaki, Masanori Yamamoto, Hiroshi Ueno
article en

Abstract

-VA score ≥2 and who successfully undergo LAAC are eligible for inclusion. A total of 500 patients undergoing LAAC will be randomised (1:1) to aspirin monotherapy versus non-antithrombotic therapy for the 45 days following OAC monotherapy. The primary outcome is a composite of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, and clinically relevant non-fatal bleeding during a maximum of 4 years of follow-up. Major bleeding or clinically relevant non-fatal bleeding is defined as Type 2, 3, or 5 bleeding, according to the Bleeding Academic Research Consortium definition. The NAPT-LAAC trial will determine the probable non-inferiority of long-term non-antithrombotic therapy to aspirin monotherapy in patients with NVAF who undergo LAAC. (ClinicalTrials.gov: NCT07125417; jRCTs031250110).

EuroInterventionVol. 22(8)
Toho University (JP), Tokai University (JP), St. Marianna University School of Medicine (JP), Keio University (JP), Kurashiki Central Hospital (JP), Sapporo Higashi Tokushukai Hospital (JP), New Tokyo Hospital (JP), Sapporo Science Center (JP), Toyohashi Heart Center (JP), Sakakibara Hospital (JP), Mitsui Memorial Hospital (JP), Toyama University Hospital (JP), Juntendo University Hospital (JP), Nagoya Heart Center (JP), Nippon Medical School Hospital (JP), Gifu Heart Center (JP), Kokura Memorial Hospital (JP), Sendai Kousei Hospital (JP), Nippon Medical School (JP), Teikyo University (JP), Kindai University (JP)
Openalex Percentile: Top 20%
Atrial Fibrillation Management and Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.